Pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 brain metastases from non-small cell lung cancer (NSCLC) Purpose To obtain information on the safety & effectiveness of the NovoTTF-100M (study device) in patients with brain metastases (tumors) from non-small cell lung cancer. Criteria 18 years of age and older Life expectancy of ≥ 3 months New diagnosis of brain metastases from NSCLC. Karnofsky performance status ≥ 70 1 inoperable brain metastasis or 2-10 brain lesions At least 1 measurable lesion You Cannot: Have known tumor mutations for which targeted agents are available for the treatment of brain mets. Have a single, operable brain metastasis Have significant edema Have midline shift > 10mm Have intractable seizures Have leptomeningeal metastases Have recurrent brain metastases Have prior whole brain radiation therapy for newly diagnosed brain metastases Have severe comorbidities Details The total duration for this study is up to 36 months. The study consists of 4 periods: Screening Period- within 21 days prior to study entry (enrollment) · Treatment Period- Once all requirements are met for participation in the study, the patient will be assigned to one of the following groups: 1. NovoTTF-100M group Radiosurgery (SRS) radiation treatment first. Then begin using the NovoTTF-100M device. Along with supportive care 2. Supportive care group Radiosurgery (SRS) radiation treatment first Then supportive care The NovoTTF-100M device will not be used Post-Treatment Follow-up Period- clinic visit 4 weeks after completion of SRS & then every 8 weeks for follow-up after that. Interested in more information? Contact Us: Radiation Oncology Services IRB: Copernicus IRB Number: Trial Type: NA Sponsor: NovoCure